Tracking a targeted cancer therapy in real patients

NCT ID NCT04727723

Summary

This study is observing how well the approved cancer drug Lutathera works for adults with advanced neuroendocrine tumors of the gut or pancreas in real-world medical practice. Researchers are following 164 patients for up to 3 years to see how long the treatment keeps the cancer from growing, how it affects their quality of life, and what side effects occur. The goal is to better understand the long-term benefits and safety of this treatment outside of a controlled clinical trial.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Alessandria, Italy

  • Novartis Investigative Site

    Bologna, Italy

  • Novartis Investigative Site

    Brescia, Italy

  • Novartis Investigative Site

    Cona, Italy

  • Novartis Investigative Site

    Florence, Italy

  • Novartis Investigative Site

    Latina, Italy

  • Novartis Investigative Site

    Meldola, Italy

  • Novartis Investigative Site

    Messina, Italy

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Negrar, Italy

  • Novartis Investigative Site

    Padua, Italy

  • Novartis Investigative Site

    Pisa, Italy

  • Novartis Investigative Site

    Reggio Emilia, Italy

  • Novartis Investigative Site

    Rionero in Volture, Italy

  • Novartis Investigative Site

    Roma, Italy

  • Novartis Investigative Site

    Rozzano, Italy

  • Novartis Investigative Site

    Torino, Italy

Conditions

Explore the condition pages connected to this study.